– Freenome examines thirty years of studies to understand differences in predictors of adherence across care settings
– Recent studies highlight increased awareness of patient environment and clinical site factors as key predictors of adherence
SOUTH SAN FRANCISCO, March 15, 2022 — Freenome, a privately held biotech company, presented research at the American Society of Preventive Oncology (ASPO) annual meeting. The systematic review explores predictors of adherence among average risk adults across three decades to understand how the factors driving adherence differ over time and by specific care setting.
CRC screening reduces CRC mortality¹ and occurs in a wide variety of care settings.² While only about two-thirds of those age >50 years are up to date on CRC screening,³ certain populations have even lower rates, including people ages 50-54 years (48%), those of Hispanic ethnicity (59%) and Medicaid recipients (53%).⁴
The research examined the frequency of more than 100 predictors of adherence organized by type of factor (e.g., test, patient, provider, site and environment) across five study settings, including primary care, specialty care, integrated system, safety net (e.g., community health centers) and regional cross-sectional surveys.
Across these settings, the study found 71.1 percent of predictors were patient-related factors, primarily demographics (i.e., age, ethnicity, and sex) and perceived importance of screening. The proportion of each predictor varied by care setting, but across all studies patient environment factors (e.g., local federal poverty level and proximity to healthcare facilities) doubled and clinic site factors (e.g., screening programs and appointment duration) tripled in the last five years.
“This research emphasizes the need for taking a more holistic view of cancer screening,” said Caitlin C. Murphy, PhD, MPH and coauthor of the study. “We need to look beyond the patient to recognize and address other factors like the patient’s neighborhood and clinic site that impact adherence.”
In addition to continued support for programmatic screening, recent studies advocated for incorporating patient preferences and culturally-competent materials to increase adherence.
“Adherence is so fundamentally tied to health equity, which is a driving force behind the work we do every day,” said Mike Nolan, CEO at Freenome. “This research underscores the importance of understanding and addressing the socioeconomic factors that affect CRC screening adherence, so we can save more lives.”
Freenome is developing a CRC screening test using a routine blood draw to detect cancer in its earliest stages. With more than 30,000 participants, Freenome’s clinical trial, PREEMPT CRC, is the largest prospective study to date for a noninvasive CRC screening in an average-risk population, with enrollment expected to close in the coming months.
¹Zauber. Dig Dis Sci. 2015. doi: 10.1007/s10620-015-3600-5
²Lin et al. JAMA. 2021. doi: 10.1001/jama.2021.4417
³Joseph et al. Prev Chronic Dis. 2018. doi: 10.5888/pcd15.170535
⁴Siegel et al. CA: A Cancer J for Clinicians. 2020. doi: 10.3322/caac.21590
Freenome is a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a standard blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California.